Showing results (31-40 of 70) with videos related to
Sort By:
Pageof 7
Communications Medicine|January 30, 2023
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIVJacopo Polvere, Massimiliano Fabbiani, Gabiria Pastore, et al.International Journal of Antimicrobial Agents|December 6, 2021
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIVDaniele Armenia, Maria Mercedes Santoro, Maria Concetta Bellocchi, et al.The Journal of Antimicrobial Chemotherapy|July 2, 2021
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort studyBarbara Rossetti, Massimiliano Fabbiani, Domenico Di Carlo, et al.HIV Medicine|February 24, 2022
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across EuropeBarbara Rossetti, Massimiliano Fabbiani, Domenico Di Carlo, et al.Journal of Global Antimicrobial Resistance|January 29, 2022
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort studyRoberta Gagliardini, Michela Baccini, Sara Modica, et al.Annals of Surgical Innovation and Research|December 19, 2009
Emergency treatment of complicated incisional hernias: a case studyFrancesco La Mura, Roberto Cirocchi, Eriberto Farinella, et al.HIV Medicine|July 13, 2023
Trend over time of HIV-1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and their drivers: A cohort study from Antiviral Response Cohort Analysis (ARCA)Ilaria Rancan, Chiara Cassol, Lucia Graziani, et al.The Journal of General Virology|October 13, 2020
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and <i>ex vivo</i> CD4 T cellsIlaria Vicenti, Filippo Dragoni, Martina Monti, et al.Le Infezioni in Medicina|December 18, 2019
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort studyGianmaria Baldin, Arturo Ciccullo, Stefano Rusconi, et al.Infectious Diseases and Therapy|November 29, 2024
Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro TrialBarbara Rossetti, Micol Ferrara, Lucia Taramasso, et al.Pageof 7